Log in to save to my catalogue

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8988051

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

About this item

Full title

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

Publisher

New York: Nature Publishing Group US

Journal title

Nature Medicine, 2021-07, Vol.27 (7), p.1187-1196

Language

English

Formats

Publication information

Publisher

New York: Nature Publishing Group US

More information

Scope and Contents

Contents

Dominantly inherited Alzheimer’s disease (DIAD) causes predictable biological changes decades before the onset of clinical symptoms, enabling testing of interventions in the asymptomatic and symptomatic stages to delay or slow disease progression. We conducted a randomized, placebo-controlled, multi-arm trial of gantenerumab or solanezumab in parti...

Alternative Titles

Full title

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8988051

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8988051

Other Identifiers

ISSN

1078-8956

E-ISSN

1546-170X,1744-7933

DOI

10.1038/s41591-021-01369-8

How to access this item